Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.

Patient-Reported Outcomes From the SERENA-6 Trial of Camizestrant + CDK4/6 Inhibitor For Emergent ESR1m During First-Line Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.